Lipidation
Also known as: Fatty acid conjugation, Acylation, Lipid modification
Lipidation is the chemical process of attaching lipid (fatty acid) molecules to peptides or proteins, enabling them to bind to albumin in the bloodstream and extending their duration of action. Lipidation is a key technology behind once-weekly peptide drugs like semaglutide and tirzepatide, where fatty acid chains protect the peptide from degradation and slow its release from albumin binding sites.
Last updated: February 1, 2026
Understanding Lipidation
Lipidation attaches fatty acid chains to peptides, dramatically extending their duration of action:
Peptide + Fatty Acid → Lipidated Peptide → Albumin Binding → Extended Half-LifeThis technology transformed peptide therapy by enabling once-daily and once-weekly dosing for drugs that would otherwise last only minutes.
How Lipidation Works
The Albumin Binding Mechanism
- Fatty acid attachment: Lipid chain added to peptide
- Albumin binding: Fatty acid binds to albumin’s lipid pockets
- Slow release: Peptide gradually dissociates from albumin
- Protected circulation: While bound, peptide is protected from degradation
- Extended action: Effective half-life increased from minutes to days
Albumin as a Carrier
| Property | Value |
|---|---|
| Plasma concentration | ~40 g/L (600 μM) |
| Half-life | ~19 days |
| Fatty acid binding sites | Multiple (7 characterized) |
| Capacity | Virtually unlimited for peptide drugs |
Lipidation Impact on Half-Life
| Drug | Lipid Modification | Half-Life | Dosing |
|---|---|---|---|
| Native GLP-1 | None | 2 minutes | N/A |
| Liraglutide | C16 fatty acid | 13 hours | Once daily |
| Semaglutide | C18 di-acid + spacer | 7 days | Once weekly |
| Native insulin | None | 5 minutes | Multiple daily |
| Insulin detemir | C14 fatty acid | 5-7 hours | Once-twice daily |
| Insulin degludec | C16 di-acid + spacer | 25 hours | Once daily |
Types of Lipid Modifications
Fatty Acid Chain Length
| Chain | Name | Albumin Affinity |
|---|---|---|
| C12 | Lauric acid | Low |
| C14 | Myristic acid | Moderate |
| C16 | Palmitic acid | High |
| C18 | Stearic acid | Very high |
| C18 di-acid | Octadecanedioic acid | Highest |
Attachment Strategies
| Strategy | Description | Example |
|---|---|---|
| Direct | Fatty acid directly on amino acid | Insulin detemir |
| Spacer | Linker between peptide and fatty acid | Semaglutide |
| Dual attachment | Two fatty acid chains | Insulin degludec |
| Branched | Multiple lipid chains | Experimental |
Semaglutide: A Lipidation Success Story
Semaglutide exemplifies optimized lipidation design:
Structural Elements
- Base peptide: GLP-1 analog (31 amino acids)
- Spacer: Mini-PEG linker (γGlu-γGlu)
- Fatty acid: C18 stearic acid di-acid
- Attachment site: Lysine at position 26
Why This Design Works
- Long spacer: Allows fatty acid to reach albumin binding pocket
- Di-acid: Increases albumin binding affinity
- Site selection: Position 26 doesn’t interfere with receptor binding
Lipidation in Drug Design
Design Considerations
| Factor | Optimization Goal |
|---|---|
| Fatty acid length | Balance affinity vs. solubility |
| Attachment site | Preserve biological activity |
| Spacer design | Optimize albumin binding geometry |
| Stability | Prevent ester hydrolysis |
Advantages Over PEGylation
| Property | Lipidation | PEGylation |
|---|---|---|
| Biodegradability | Fully metabolized | Limited |
| Immunogenicity | Minimal | Anti-PEG antibodies possible |
| Size increase | Minimal | Significant |
| Activity retention | Often high | Variable |
| Manufacturing | Simpler | Complex purification |
Lipidated Drug Examples
GLP-1 Receptor Agonists
| Drug | Fatty Acid | Half-Life | Dosing |
|---|---|---|---|
| Liraglutide | C16 palmitic | 13 hours | Daily |
| Semaglutide | C18 di-acid | 168 hours | Weekly |
| Tirzepatide | C20 di-acid | 5 days | Weekly |
Insulin Analogs
| Drug | Modification | Duration |
|---|---|---|
| Insulin detemir | C14 myristic | Intermediate |
| Insulin degludec | C16 di-acid | Ultra-long |
Challenges and Solutions
| Challenge | Solution |
|---|---|
| Reduced solubility | Optimize fatty acid length, add spacer |
| Injection site reactions | Formulation optimization |
| Activity reduction | Screen attachment sites |
| Aggregation | Formulation additives |
Frequently Asked Questions
Why is lipidation better than PEGylation for GLP-1 drugs?
Lipidation offers several advantages for GLP-1 drugs:
- Albumin binding provides consistent extended release
- No immunogenic concerns (anti-PEG antibodies)
- Smaller size allows subcutaneous injection without viscosity issues
- Natural metabolic pathway for fatty acid clearance
- Semaglutide (lipidated) has better half-life than any PEGylated GLP-1
Does the fatty acid get metabolized?
Yes, fatty acid chains are fully metabolized by normal lipid pathways. This is an advantage over PEG, which has limited biodegradability. The peptide portion is also metabolized normally once released from albumin.
Can lipidation be combined with other modifications?
Yes, combination strategies are used:
- Semaglutide: Lipidation + amino acid substitutions (Aib)
- Tirzepatide: Lipidation + dual receptor targeting
- Some experimental peptides combine lipidation with cyclization or other stabilizing modifications
The goal is complementary benefits from each modification.
Related Peptides
Related Terms
Disclaimer: This glossary entry is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider for medical questions.